Recent developments include a major direct offering to bolster operations, promising clinical data for motixafortide combinations in pancreatic cancer ahead of ASCO 2025, and routine earnings reports highlighting ongoing activities.

• BioLineRx announced a major direct offering to bolster operations, enhancing its financial resources for development activities [N1].
• The company reported promising combination data for motixafortide in pancreatic ductal adenocarcinoma (PDAC) ahead of ASCO 2025, indicating clinical progress in solid tumor indications [N2].
• BioLineRx was included in a pre-market earnings report for March 31, 2025, reflecting ongoing market and operational updates [N3].

BioLineRx’s strategic out-licensing of motixafortide rights has reduced operational costs and cash burn, allowing the company to focus on advancing development programs in oncology and rare diseases. The ongoing investigator-initiated trials and collaboration with Hemispherian for GLIX1 represent potential avenues for clinical progress. The recent major direct offering strengthens the company’s financial position to support operations and development activities. The company’s disciplined approach to in-licensing and development may enable it to build a pipeline of innovative therapies addressing unmet medical needs.

BioLineRx faces risks related to its limited direct commercialization capabilities following the out-licensing of motixafortide rights and dependence on partners for revenue generation. The company has a history of operating losses and an accumulated deficit, with ongoing needs for capital to fund research and development. Clinical development programs carry inherent risks of failure or delay, and the company’s liquidity position requires careful management. Market conditions, regulatory challenges, and the ability of partners to successfully commercialize licensed products are additional uncertainties that could impact financial performance and operational continuity.

BioLineRx’s moat is based on its specialized focus on oncology and rare diseases, leveraging in-licensing strategies to build a pipeline of differentiated therapeutic candidates. The company’s approach to structuring deals with modest upfront payments and success-based milestones aligns incentives with partners and manages financial risk. Its first approved product, APHEXDA (motixafortide), and associated licensing agreements provide a foundation of royalties and milestones that support ongoing development activities. The company’s expertise in asset scouting, clinical validation, and partnerships contributes to its ability to advance novel therapies with potential clinical and commercial value. However, the company’s reliance on out-licensing partners for commercialization and revenue generation introduces dependency risks.

• Dependence on Licensing Partners: BioLineRx relies on its commercialization partners, Gloria and Ayrmid, for generating revenues from motixafortide, which subjects the company to risks related to partners’ commercial success and milestone achievement.
• Clinical Development Risks: The company’s pipeline and ongoing trials, including those for motixafortide in solid tumors and GLIX1, face typical clinical development uncertainties such as trial outcomes, regulatory approvals, and timelines.
• Financial and Liquidity Risks: BioLineRx has an accumulated deficit and reported net losses, with liquidity dependent on capital raises, milestone payments, and managing cash burn. The company has loan obligations with BlackRock that require scheduled repayments.
• Operational Risks: The shutdown of U.S. commercialization operations and refocus on development activities reduce operational scale and may impact future growth opportunities.

• BioLineRx Ltd. is a biopharmaceutical company focused on developing therapies in oncology and rare diseases, headquartered in Israel.
• The company’s first approved product is APHEXDA (motixafortide), approved in September 2023 for stem-cell mobilization in multiple myeloma.
• BioLineRx out-licensed motixafortide rights for all indications in substantially all of Asia to Gloria in October 2023.
• In November 2024, BioLineRx out-licensed global rights (excluding Asia) to motixafortide for all indications except solid tumors to Ayrmid.
• Following the November 2024 out-licensing, BioLineRx ceased independent commercialization in the U.S. and refocused on development activities in Israel with reduced cash burn.
• The company retains rights to develop motixafortide for solid tumors outside Asia, including pancreatic cancer, with ongoing investigator-initiated Phase 2b trials supported by Columbia University and Regeneron.
• BioLineRx entered a collaboration in September 2025 with Hemispherian AS to develop GLIX1, a first-in-class oral small molecule targeting D.
• The company’s business model emphasizes in-licensing assets with potential for differentiation in oncology and rare diseases, focusing on cost-effective clinical development and success-based payments.
• BioLineRx has generated limited direct product revenues, primarily from royalties and milestone payments under licensing agreements.
• For the fiscal year ended December 31, 2025, BioLineRx reported revenues of $1.18 million and a net loss of $2.03 million.
• The company’s cash and cash equivalents were $3.25 million as of December 31, 2025, with current assets of $23.68 million and current liabilities of $12.12 million, yielding a current ratio of 1.95 and a cash ratio of 0.27.
• Research and development expenses decreased to $8.1 million in 2025, reflecting lower motixafortide expenses and initiation of the GLIX1 project.
• Sales and marketing expenses were zero in 2025 following the shutdown of U.S. commercial operations in late 2024.
• General and administrative expenses decreased by 50.3% to $3.1 million in 2025, partly due to reversal of a provision for doubtful accounts.
• BioLineRx has a secured loan agreement with BlackRock with repayments scheduled through December 2027, including interest at 9.5% per annum.
• The company completed a registered direct offering and an ATM equity offering to bolster operations in early 2026.
• Management includes CEO Philip A. Serlin (since 2016), CFO Mali Zeevi, and Chief Development Officer Ella Sorani.
• The board includes experienced directors with backgrounds in biotech, pharmaceuticals, and finance.
• BioLineRx’s accumulated deficit was $401 million as of December 31, 2025.
• The company’s strategy includes advancing motixafortide in solid tumors and developing new assets through partnerships and in-licensing.